

**ALUME BIOSCIENCES**  
**EXPANDED ACCESS POLICY**

According to the Food and Drug Administration (FDA), “Expanded Access, sometimes called Compassionate Use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.”

At Alume Biosciences, we are committed to developing safe and effective nerve imaging agents. Our investigational product, ALM-488, is currently in a Phase 1/2 clinical trial in which the potential risks and benefits of this experimental treatment are being evaluated. Until substantial scientific evidence to support the safety and efficacy of ALM-488 is available, expanded or compassionate use of ALM-488 is not appropriate.

If you have additional questions about this policy, please speak with your physician or contact [clinical.trial@alumebiosciences.com](mailto:clinical.trial@alumebiosciences.com). We anticipate acknowledging and responding to messages sent to this email address within five business days.